Long-term progression-free survival of apatinib monotherapy for relapsed ovarian cancer: a case report and literature review

Ovarian cancer is the deadliest gynecologic malignancy, which poses a great threat to female health. Anti-angiogenic therapy could bring clinical benefit for patients with ovarian cancer. Apatinib, an oral small-molecule vascular endothelial growth factor receptor-2 inhibitor, has shown notable ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Di, Huang, Jiaqi, Sun, Yulan, Guo, Qisen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6529614/
https://www.ncbi.nlm.nih.gov/pubmed/31190866
http://dx.doi.org/10.2147/OTT.S198946

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6529614/
https://www.ncbi.nlm.nih.gov/pubmed/31190866
http://dx.doi.org/10.2147/OTT.S198946

Ejemplares similares